Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor-derived LMP-specific cytotoxic T-lymphocytes
- Development stage
- Discontinued
- Lead developer
- IRCCS San Matteo Foundation
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Donor-derived latent membrane protein (LMP)-specific cytotoxic T-lymphocytes (CTLs) are an adoptive cellular immunotherapy developed by New York Medical College for the treatment of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma. This therapy involves the ex vivo expansion of T-cells from an HLA-matched donor that are specifically reactive against EBV-associated antigens, specifically Latent Membrane Protein 1 (LMP1) and Latent Membrane Protein 2 (LMP2). These proteins are frequently expressed in EBV-associated malignancies like Hodgkin lymphoma and serve as targets for the immune system. In the clinical setting, these CTLs are infused following a reduced-intensity allogeneic stem cell transplant to provide a targeted graft-versus-lymphoma effect while minimizing the risk of graft-versus-host disease, aiming to eliminate residual EBV-positive tumor cells.
- Other names
- allogeneic donor derived LMP specific cytotoxic T-lymphocyteLMP-specific CTLsEBV-LMP-specific CTLslatent membrane protein-specific cytotoxic T-lymphocytes
02
Targets
pMHC-I (Peptide–MHC class I complex)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on donor-derived LMP-specific cytotoxic T-lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor-derived LMP-specific cytotoxic T-lymphocytes.